Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
Synamics Therapeutics ApS
APS
Active
Advertising protection
CVR 44258048
Fruebjergvej 3, 2100
København Ø
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2023 · 2 years old
3 employees
Monitor
Share
Denmark
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Synamics Therapeutics ApS
Overview
Financials
People & ownership
Related companies
Loading company…
People & ownership
Management
Actively employed in the business
Name
Role
Member since
Current (3)
AJ
Albert Jelke Kooistra
Founder
Founder
2023
VZ
Violet Zahedi
Management
Management
2023
HT
Helder Takashi Imoto Nakaya
Founder
Founder
2023
Board of directors
Non-executive oversight
Name
Role
Member since
Current (4)
AD
Aaron Daniel Capar
Chairman
Chairman
2023
AJ
Albert Jelke Kooistra
Board of Directors
Board of Directors
2023
PF
Per Falholt
Board of Directors
Board of Directors
2024
VZ
Violet Zahedi
Board of Directors
Board of Directors
2023
Former (1)
HT
Helder Takashi Imoto Nakaya
Board of Directors
Board of Directors
2023 – 2024
Shareholders
As of last annual report
Synamics Therapeutics Inc. — 100%
LILLE FREDERIKSLUND INVEST ApS — 10–14.99%
Continuum Holdings Inc. — 25–33.32%
Albert Jelke Kooistra — 10–14.99%
Helder Takashi Imoto Nakaya — 10–14.99%
Steen Riisgaard — 10–14.99%
Xivius LLC — 25–33.32%
Violhuset ApS — 10–14.99%
Lille Frederikslund Tech Invest ApS — 10–14.99%
100%
Shareholder
Type
Ownership
Votes
Since
Synamics Therapeutics Inc.
Company
100%
100%
2025
LILLE FREDERIKSLUND INVEST ApS
Company
10–14.99%
10–14.99%
2024
Continuum Holdings Inc.
Company
25–33.32%
25–33.32%
2024
Albert Jelke Kooistra
Individual
10–14.99%
10–14.99%
2024
Helder Takashi Imoto Nakaya
Individual
10–14.99%
10–14.99%
2024
Steen Riisgaard
Individual
10–14.99%
10–14.99%
2024
Xivius LLC
Company
25–33.32%
25–33.32%
2024
Violhuset ApS
Company
10–14.99%
10–14.99%
2024
Lille Frederikslund Tech Invest ApS
Company
10–14.99%
10–14.99%
2024
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
More on Synamics Therapeutics ApS
Overview →
Headline figures, risk assessment and company summary
Financials & key figures →
Revenue, EBITDA, balance sheet and 5-year trend
Related companies →
Corporate hierarchy, parent and subsidiary network